Flatworm (planarian)
Download
1 / 76

Flatworm (planarian) - PowerPoint PPT Presentation


  • 68 Views
  • Uploaded on

Flatworm (planarian). Newt. MRL mice. Nature. 2012 Sep 27;489(7417):561-5. doi: 10.1038/nature11499. Skin shedding and tissue regeneration in African spiny mice (Acomys).Seifert AW, Kiama SG, Seifert MG, Goheen JR, Palmer TM, Maden M. Stem Cell Development. Differentiation. functional

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Flatworm (planarian)' - nara


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Flatworm (planarian)

Newt

MRL mice

Nature. 2012 Sep 27;489(7417):561-5. doi: 10.1038/nature11499. Skin shedding and tissue regeneration in African spiny mice (Acomys).Seifert AW, Kiama SG, Seifert MG, Goheen JR, Palmer TM, Maden M.


Stem Cell Development

Differentiation

functional

maturation

Adult stem/

progenitors

chronological aging

Senescence

PCD (apoptosis)

Death

ESCs


Stem Cells & Cancer

  • Three tumor biology puzzles:

  • Most tumors are of a clonal origin but tumor cells are heterogeneous.

  • It is very difficult to establish stable tumor cell lines from tumors.

  • Large numbers of established tumor cells have to be injected to re-initiate

    an orthotopic tumor in mice.

  • Key reviews:

  • Reya T et al. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111, 2001.

  • Dick JE. Stem cell concepts renew cancer research. Blood 112: 4793-4807, 2008.

  • Visvader JE, and Lindeman GJ. Cancer Stem Cells: Current Status and Evolving Complexicities. Cell Stem Cell 10: 717-728, 2012.

  • 4. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res, 22(3):457-472, 2012.

  • 5. Magee JA, Piskounova E, & Morrison SJ. Cancer Stem Cells: Impact, Heterogeneity,

  • and Uncertainty. Cancer Cell 21: 283-296, 2012.

  • (Dean Tang, Basic Concepts of Tumor Biology, Oct 31, 2012)


Stem Cells & Cancer

1. Characteristics & Definition

2. SC Identification

3. SC Niche & Plasticity

4. SCs & Cancer

5. Cancer Stem Cells (CSCs)


Stem Cells

  • Rare

  • Generally small

  • - Normally localized in a ‘protected’ environment called

  • NICHE, where they only occasionally divide.

  • - But they possess HIGH PROLIFERATIVE POTENTIAL

  • and can give rise to large clones of progeny in vitro or in

  • vivo following injury or appropriate stimulation.

  • - Possess the ability to SELF-RENEW (i.e., asymmetric

  • or symmetric cell division)

  • - Can generate (i.e., DIFFERENTIATE into) one or

  • multiple or all cell types (uni-, oligo-, multi-, pluri-, or

  • toti-potent).


symmetric SC renewal

asymmetric cell

division (ACD)

symmetric SC commitment

(differentiation)

SC

Committed progenitor cells

Tang, Cell Res. 2012


Cell lineage development: Self-renewal, proliferation, & differentiation

Differentiation

Transformation

probability

Self-renewal

LT-SC

ST-SC

Late

progenitors

Differen-

tiating cells

Differen-

tiated cells

Early

progenitors

Proliferation

Commitment

Niche

Expansion

Differentiation

Tang, Cell Res. 2012


Embryonic Stem Cells (ESCs) differentiation

  • Mouse ESCs were generated early 1980s by Evans and

  • Martin.

  • mES cells are cultured on mouse fibroblast feeders

  • (irradiated or mitomycin C-treated) together with LIF.

  • .mES cells are widely used in gene targeting.

  • Human ES (hES) cells were first created by Jim Thomson

  • (Uni. Wisconsin) in 1998.

  • hES cells were initially cultured also on mouse fibroblast

  • feeders but without LIF. Now they can be maintained in

  • defined medium with high bFGF (100 ng/ml), activin,

  • and some other factors.


How can hES cells be derived? differentiation

  • Leftover or dead-end IVF embryos (PGD)


16-cell morula differentiation


Primitive ectoderm differentiation

Trophectoderm

Primitive Endoderm

A. Nagy


ES cells differentiation

A. Nagy


TS cells differentiation

A. Nagy


A. Nagy differentiation


A. Nagy differentiation


A. Nagy differentiation


heart differentiation

pancreas

testis

liver

brain

kidney

A. Nagy


Other ‘embryonic’ SCs differentiation

Germline Stem Cells (GSC)

Cord Blood Stem Cells (CB-SC)

  • Derived from umbilical cord

  • Primarily blood stem cells

  • Also contain mesenchymal stem cells that can differentiate

  • into bone, cartilage, heart muscle, brain, liver tissue etc.

  • *CB-SC could be stimulated to differentiate into neuron,

  • endothelial cell, and insulin-producing cells


Stem Cells & Cancer differentiation

1. Characteristics & Definition

2. SC Identification

3. SC Niche & Plasticity

4. SCs & Cancer

5. Cancer Stem Cells (CSCs)


Functional Assays of Stem Cells differentiation

(Candidate) Stem Cells

Stem Cells in situ

(Xeno)Transplantation

Lineage tracing


How to identify and characterize differentiation

(adult) stem cells?

Marker analysis

Label-retaining cells (LRC): Pulse-chase exper.

Clonal/clonogenic assays

Functional analysis: Side population (SP) assay

Functional analysis: Aldefluor assay

Cell size-based enrichment

Genetic marking & lineage tracing


Hematopoietic stem/progenitor cell lineages differentiation

Lin-CD34+CD38-CD45RA-Thy1+RholoCD49f+

(Notta F…..Dick JE. Science 333, 218-221, 2011)

Lin-Sca1+ckit+CD150+CD48-

(20%-50% such mouse BM cells are SCs)

(~1:5,000 or 0.02%;

lifetime self-renewal)

(~1:1,000 or 0.1%;

self-renewal for 8 wks)

(No self-renewal)

Passegué, Emmanuelle et al. (2003) Proc. Natl. Acad. Sci. USA 100, 11842-11849

Till JE & McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.

Radiat. Res 14, 213-222, 1961.


(Nestin) differentiation

(PDGFRa)

(Mash-1)

(NeuM)

(Pax6)

(A2B5)

(GFAP)

(MBP)

(NG2)


Sue Fischer differentiation


How to identify and characterize differentiation

(adult) stem cells?

Marker analysis

Label-retaining cells (LRC): Pulse-chase exper.

Clonal/clonogenic assays

Functional analysis: Side population (SP) assay

Functional analysis: Aldefluor assay

Cell size-based enrichment

Genetic marking & lineage tracing


Till JE & McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat. Res 14, 213-222, 1961. [The earliest report in which putative stem cells were identified by their ability to retain labeled radionucleotides for long period of time]

Cotsarelis G, Cheng SZ, Dong G, Sun TT & Lavker RM. Existence of slow-cycling libmal epithelial basal cells that can be preferentially stimulated to proliferate: Implications on epithelial stem cells. Cell 57, 201-209, 1989.

Cotsarelis G, Sun TT, & Lavker RM. Label-retaining cell reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell 61, 1329-1337, 1990.


LRCs in the Bulge & BM ARE Stem Cells radiation sensitivity of normal mouse bone marrow cells. Radiat. Res 14, 213-222,

Tumbar T et al., Defining the epithelial stem cell niche in skin. Science 303, 359-363, 2004.

Blanpain, C., et al., Self-renewal, multipotency, and the existence of two cell populations in an epithelial stem

cell niche. Cell 118, 635-648, 2004.

Fuchs et al., Cell 116, 769, 2004

Fuchs E: The tortoise and the hair: Slow-cycling cells in the stem cell race. Cell 137, 811-819, 2009.

Fuchs E & Horsley V. Ferreting out stem cells from their niches. Nat Cell Biology 13: 513-518, 2011.

Wilson A et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis

and repair. Cell 135, 1118-1129, 2008.

Foudi A et al. Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells. Nat. Biotechnol.

27, 84-90, 2009.


Not All Stem Cells Are Slow-Cycling radiation sensitivity of normal mouse bone marrow cells. Radiat. Res 14, 213-222,

‘…. and even for the ones that do, approximately only 5-6 divisions of the

label-retaining stem cell or its progeny can be monitored after a pulse-chase before

the label has diluted out to the point where it can no longer be traced’.

Fuchs E & Horsley V. Ferreting out stem cells from their niches. Nat Cell Biology 13: 513-518, 2011.

Li L & Clevers H. Co-existence of quiescent and active adult stem cells in mammals. 327, 542-545, 2010.

Not All Slow-Cycling Cells Are Stem Cells


How to identify and characterize radiation sensitivity of normal mouse bone marrow cells. Radiat. Res 14, 213-222,

(adult) stem cells?

Marker analysis

Label-retaining cells (LRC): Pulse-chase exper.

Clonal/clonogenic assays

Functional analysis: Side population (SP) assays

Functional analysis: Aldefluor assay

Cell size-based enrichment

Genetic marking & lineage tracing


E radiation sensitivity of normal mouse bone marrow cells. Radiat. Res 14, 213-222,

Rheinwald JG & Green H. Serial cultivation of human epidermal keratinocytes: The formation

of keratinizing colonies from single cells. Cell 6, 331-343, 1975.

Sun TT

Cell 9, 511-521, 1976

Nature 269, 489-493, 1977

Cell 14, 469-476, 1978

Fuchs E

Cell 19, 1033-1042, 1980

Cell 25, 617-625, 1981

Barrandon Y

PNAS 82, 5390-4, 1985

Cell 50, 1131-1137, 1987

Rice RH

Cell 11, 417-422, 1977

Cell 18, 681-694, 1979

Watt FM

JCB 90, 738-742, 1981


Anchorage- radiation sensitivity of normal mouse bone marrow cells. Radiat. Res 14, 213-222,

independ.

survival

Plating efficiency

Clonogenic

‘In-gel’ assays

(plate cells at

low density)

Prolif. potential

Prolif.

Clonal

*Plate cells at

clonal density

(50-100 cells/well

in 6-well plate

or 10-cm dish

or T25 flask)

‘On-gel’ assays

(plate at low density)

*Plate single cells

into 96-well plates

(or using flow sorting)

- limiting dilution

Gels: Agar

Agarose

Methylcellulose

Matrigel

Poly-HEMA

fibroblasts

Spheres

(sphere-formation

assays)

Colonies

(colony-formation

assays)

Holoclone

Mero- or paraclone

A colony/sphere: a 3-D structure

Efficiency (%)

Colony/sphere size (cell number)

Colony/sphere development (tracking)

Immunostaining/tumor exp.

CLONAL vs CLONOGENIC ASSAYS

A clone: a two-dimensional structure

Cloning efficiency (CE; %)

Clonal size (cell number/clone)

Clonal development (tracking)

Clone types


Mixing experiments to demonstrate the clonality of clones spheres
Mixing Experiments radiation sensitivity of normal mouse bone marrow cells. Radiat. Res 14, 213-222, to Demonstrate the Clonality of Clones/Spheres

DU145:DU145 GFP (1:1) Clonal Assay

phase

DU145:DU145 GFP (1:1) MC

GFP

DU145 RFP:DU145 GFP (1:1) MC

Pastrana E, Silva-Vargas V, and Doetsch F.

Eyes wide open: A critical review of sphere-formation as an assay of stem cells.

Cell Stem Cell 8, 486-498, 2011


How to identify and characterize radiation sensitivity of normal mouse bone marrow cells. Radiat. Res 14, 213-222,

(adult) stem cells?

Marker analysis

Label-retaining cells (LRC): Pulse-chase exper.

Clonal/clonogenic assays

Functional analysis: Side population (SP) assays

Functional analysis: Aldefluor assay

Cell size-based enrichment

Genetic marking & lineage tracing


Goodell MA et al. Isolation and functional properties of murine hematopoietic stem cells that are

replicating in vivo. J. Exp. Med. 183, 1797-1806, 1996.

Golebiewska A, Brons NH, Bjerkvig R, and Niclou SP. Critical appraisal of the side population assay

in stem cell and cancer stem cell research. Cell Stem Cell 8, 136-147, 2011.


Zhou et al., murine hematopoietic stem cells that are

Nature Med

7, 1028, 2001

Bcrp (ABCG2) is a major mediator of the SP phenotype


How to identify and characterize murine hematopoietic stem cells that are

(adult) stem cells?

Marker analysis

Label-retaining cells (LRC): Pulse-chase exper.

Clonal/clonogenic assays

Functional analysis: Side population (SP) assays

Functional analysis: Aldefluor assay

Cell size-based enrichment

Genetic marking & lineage tracing


Kastan MB murine hematopoietic stem cells that are et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic

progenitor cells. Blood 75, 1947-1960, 1990.

Jones RJ et al., Assessment of aldehyde dehydrogenase in viable cells. Blood 85, 2742-46, 1995.

Storms RW et al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde

dehydrogenase activity. PNAS 96, 9118-9123, 1999.

Alison MR, Guppy NJ, Lim SML, & Nicholson LJ. Finding cancer stem cells: Are aldehyde dehydrogenases fit

for purpose? J Pathol. 222, 335-344, 2010.

Ma I & Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev

and Report 7, 292-306, 2011.

*ALDH1A1 and ALDH3A1: Seem to be the major isozymes mediating the Aldefluor phenotype and are preferentially expressed in SC.

*ALDH superfamily: 19 putatively functional genes in 11 families and 4 subfamilies. ALDH superfamily of NAD(P)+-dependent enzyme catalyzes oxidations of aldehydes to carboxylic acids.


How to identify and characterize murine hematopoietic stem cells that are

(adult) stem cells?

Marker analysis

Label-retaining cells (LRC): Pulse-chase exper.

Clonal/clonogenic assays

Functional analysis: Side population (SP) assays

Functional analysis: Aldefluor assay

Cell size-based enrichment

Genetic marking & lineage tracing


Fuchs E & Horsley V. Ferreting out stem cells from their niches. Nature Cell Biology 13: 513-518, 2011.


Fuchs E & Horsley V. Ferreting out stem cells from their niches. Nature Cell Biology 13: 513-518, 2011.

Liver J et al., Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system.

Nature 450, 56-62, 2007.

Snippert HJ et al., Intestinal crypt homeostasis results from neutral competition between symmetrically dividing

Lrg stem cells. Cell 143, 134-144, 2010.


Stem Cells & Cancer niches. Nature Cell Biology 13: 513-518, 2011.

1. Characteristics & Definition

2. SC Identification

3. SC Niche & Plasticity

4. SCs & Cancer

5. Cancer Stem Cells (CSCs)


Stem Cell Niche in Hair Follicles: The Bulge niches. Nature Cell Biology 13: 513-518, 2011.

Moore KA & Lemischka IR. Science 311, 1880-1885, 2006


Bulge Stem Cells niches. Nature Cell Biology 13: 513-518, 2011.

Tumbar et al., Science 303, 359-363, 2004; Fuchs et al., Cell 116, 769, 2004


Stem Cell Niche in Small Intestine: The Crypt niches. Nature Cell Biology 13: 513-518, 2011.

Moore KA & Lemischka IR. Science 311, 1880-1885, 2006

Barker N et al., Cell Stem Cell 11: 452-460, 2012.


Stem Cell Niches in BM niches. Nature Cell Biology 13: 513-518, 2011.

Moore KA & Lemischka IR. Science 311, 1880-1885, 2006

Naveiras O et al., Bone-marrow adipocytes as negative regulators of the hematopoietic

microenvironment. Nature 460, 259, 2009.

Mendez-Ferrer, S et al., Mesenchymal and hematopoietic stem cells form a unique bone

marrow niche. Nature 466, 829-834, 2010.


Stem cell lineage niches. Nature Cell Biology 13: 513-518, 2011.

Differentiated

cells

Progenitors/

Precursor cells

Other

differ.

cell(s)

Senescence

Death (PCD)

Stem cells


“Transdifferentiation” of Stem Cells niches. Nature Cell Biology 13: 513-518, 2011.

*First report: Long-term cultured adult brain (stem) cells can reconstitute the whole blood in lethally irradiated mice (Bjornson et al., Science 283, 534-537, 1999).

*Cells from skeletal muscle have hematopoietic potential (Jackson et al., PNAS 96, 14482-14486, 1999) and can also “differentiate” into many other cell types (Qu-Petersen, Z, et al., JCB 157, 851- 864, 2002).

*CNS “SCs” can “differentiate” into muscle cells (Clarke et al., Science 288, 1660-1663, 2000; Galli et al., Nat. Neurosci 3, 986-991, 2000; Tsai and McKay, J. Neurosci 20, 3725-3735, 2000).

*Vice versa, “SCs” from blood or bone marrow can “transdifferentiate” into muscle (Ferrari et al., Science 279, 1528-1530, 1998; Gussoni et al., Nature 401, 390-394, 1999), hepatocytes (Petersen et al., Science 284, 1168-1170, 1999; Lagasse et al., Nat Med 6, 1229-1234, 2000), cardiac myocytes (Orlic et al., Nature 410, 701-705, 2001), or neural cells (Mezey et al., Science 290, 1779-1782, 2000; Brazelton et al., Science 290, 1775-1779, 2000).

*Bone marrow appears to contain two distinct SCs: the HSC and MSC. A single HSC could contribute to epithelia of multiple organs of endodermal and ectodermal origin (Krause et al., Cell 105 369-377, 2001). MSC, on the other hand, can adopt a wider range of fates (endothelial, liver, neural cells, and perhaps all cell types) (Pittenger et al., Science 284, 143-146, 1999; Schwartz et al., JCI 109, 1291-1302, 2002; Jiang et al., Nature 418, 41-49, 2002).

*Pluripotent “SCs” have also been isolated from skin that can “differentiate” into neural cells, epithelial cells, and blood cells (Toma et al., Nat Cell Biol. 3, 778-784, 2001)

*Highly purified adult rat hepatic oval “stem’ cells, which are capable of differentiating into hepatocytes and bile duct epithelium, can “trans-differentiate” into pancreatic endocrine hormone- producing cells when cultured in a high glucose environment (Yang et al., PNAS 99, 8078-

8083, 2002)


De-differentiation: Cell-cycle re-entry niches. Nature Cell Biology 13: 513-518, 2011.

*Many ‘post-mitotic’ cells such as hepatocytes, endothelial cells, and Schwann cells have long

been known to retain proliferative (progenitor) potential.

*Dedifferentiation is a genetically regulated process that may ensure a return path to the

undifferentiated state when necessary (Katoh et al., PNAS 101, 7005, 2004).

*Regeneration of male GSC by spermatogonial dedifferentiation in vivo (Brawley and Matunis,

Science 304, 1331, 2004).

*Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors

(Nature 449, 473-477, 2007).

*During Salamander limb regeneration, complete de-differentiation to a pluripotent state

is not required – Progenitor cells in the blastema keep a memory of their tissue origin

(Nature 460, 60-65, 2009).

*Epigenetic reversion of post-implantation epiblast to pluripotent embryonic cells (Nature,

461, 1292-1295, 2009).

*Evidence for cardiomyocyte renewal in humans (Bergmann O et al., Science 324, 98-102, 2009).

(Cardiomyocytes turn over at an estimated rate of ~1% per year at age 20, declining to 0.4%

per year at age 75. At age 50, 55% of human cardiomyocytes remain from birth while 45%

were generated afterward. Over the first decade of life, cardiomyocytes often undergo a final

round of DNA synthesis and nuclear division without cell division, resulting in ~25% of human

cardiomyocytes being binucleated.)

*Neuregulin 1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury

(Bersell et al., Cell, 138, 257-270, 2009).

*MafB/c-Maf deficiency enables self-renewal of differentiated functional macrophages (Aziz A,

et al., Science 326, 867-871, 2009).


Pancreatic niches. Nature Cell Biology 13: 513-518, 2011.b-cells: Interesting insulin-producing cells

*Insulin-producing b-cells in adult mouse pancreas can

self-duplicate during normal homeostasis as well as

during injury (Dor et al., Nature 429, 41, 2004).

*In vivo reprogramming of adult pancreatic exocrine cells to b

cells using 3 TFs (Ngn3, Pdx1, and Mafa), suggesting a

paradign for directing cell reprogramming without

reversion to a pluripotent cell state (Zhou et al., Nature

455, 627-632, 2008).

*In response to injury, a population of pancreatic progenitors

can generate glucagon-expressing alpha cells that then

transdifferentiate (with ectopic expression of Pax4) into

beta cells (Collmbat et al, Cell 138, 449-462, 2009).

*Conversion of adult pancreatic a-cells to b-cells after extreme

b-cell loss (Nature 464, 1149-1154, 2010).


CELL 126, 652-655, 2006 niches. Nature Cell Biology 13: 513-518, 2011.

NUCLEAR REPROGRAMMING


Induced Pluripotent Cells (iPS cells) niches. Nature Cell Biology 13: 513-518, 2011.

(Infection of somatic cells with 2-4 factors:Oct4, Sox2, Klf-4, Myc)

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006 Aug 25;126(4):663-76.

Maherali N, ……., Hochedlinger K. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell. 2007 Jun 7;1(1):55-70.

Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007 Jul 19;448(7151):313-7.

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from

adult human fibroblasts by defined factors. Cell 131, 861-872, 2007.

Yu J, ……, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007 Dec

21;318(5858):1917-20.

Hanna J, …. Jaenisch R. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin (Science,

318, 1920-1923, 2007).

Nakagawa M, …… Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2008 Jan;26(1):101-6.

Park IH, …….. Daley GQ. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008 Jan 10;451(7175):141-6.

Kobayashi T et al., Generation of rat pancreas in mouse by interspecific blastocyst injection of pluripotent stem cells. Cell 142,

787-799, 2010.

*Up to now: ~5,000 PubMed publications on iPS cells!

*Yamanaka S: Elite and stochastic models for induced pluripotent stem cell generation.

Nature 460: 49-52, 2009.

*Yamanaka S & Blau HM. Nuclear reprogramming to a pluripotent state by three

approaches. Nature 465, 704, 2010


Development and epigenetic re programming
Development and epigenetic (re)programming niches. Nature Cell Biology 13: 513-518, 2011.

Hochedlinger 2009, Development 136, 509-523


Direct Reprogramming and Lineage Conversion of Cells niches. Nature Cell Biology 13: 513-518, 2011.

Nicholas CR & Kriegstein AR. Cell reprogramming gets direct. Nature 463, 1031-1032, 2010.

Vierbuchen T et al., Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463,

1035-1041, 2010 (Ascl1, Brn2, and Myt1l).

Ieda M, et al., Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell

142, 375-386, 2010 (Gata4, Mef2c, and Tbx5).

Bonfanti P, et al., Microenvironmental reprogramming of thymic epithelial cells to skin multipotent stem

cells. Nature 466, 978-982, 2010.

Bussard KM, et al., Reprogramming human cancer cells in the mouse mammary gland. Cancer Res 70,

6336-6343, 2010.


Stem Cells & Cancer niches. Nature Cell Biology 13: 513-518, 2011.

1. Characteristics & Definition

2. SC Identification

3. SC Niche & Plasticity

4. SCs & Cancer

5. Cancer Stem Cells (CSCs)


Stem Cells & Tumorigenesis niches. Nature Cell Biology 13: 513-518, 2011.

(Terminal) differentiation

functional

maturation

Senescence

Perinatal stem/

progenitors

PCD

Death

Adult Stem/

Progenitor Cells

ESCs

Tumor cells


Several fundamental tumor biology questions niches. Nature Cell Biology 13: 513-518, 2011.

Why is it so difficult to establish tumor cell lines

from established tumors or even metastases?

2. Why tens or hundreds of thousands of established

tumor cells have to be injected to initiate an

orthotopic tumor?

3. Tumors are clonal (i.e., all tumors were initially

derived from ‘going bad’ of one cell) but why is the

tumor itself heterogeneous?


Tumorigenecities of Orthotopically Implanted Prostate Cancer Cells

Cell type Cell# injected Incidence Latency (days)

Du145 1,000 0/4

10,000 0/4

100,000 1/4 103

500,000 3/5 53, 53, 59

LAPC4 100 0/4

1,000 0/4

10,000 0/4

100,000 0/4

500,000 3/6 43, 43, 48

LAPC9 100 0/3

1,000 0/9

10,000 4/8 46, 53, 75, 75

100,000 6/9 32, 42, 42, 45, 62, 69

1,000,000 4/4 48, 56, 56, 69


Nanog Cancer Cells

CK5

PSA

CD57

AR


Several fundamental tumor biology questions Cancer Cells

Why is it so difficult to establish tumor cell lines

from tumors or even metastases?

2. Why tens or hundreds of thousands of established

tumor cells have to be injected to initiate an

orthotopic tumor?

3. Tumors are clonal (i.e., all tumors were initially

derived from ‘going bad’ of one cell) but why is the

tumor itself heterogeneous (i.e., comprising

multiple cell types)?

These questions can be potentially explained by the

presence of stem-like cells in the tumor, i.e., tumor (or

cancer) stem cells


Cancer stem cells (CSC): Tumorigenic cells Cancer Cells

Hewitt, HB. Studies of the quantitative transplantation of mouse sarcoma. Brit. J. Cancer. 7, 367-

383, 1953 (~0.01% of the tumor cells are tumor stem cells; limiting dilution method).

Bruce, W.R & van der Gaag, H. A quantitative assay for the number of murine lymphoma cells

capable of proliferation in vivo. Nature 199, 79-80, 1963 (~0.8% total cells forming

spleen colonies).

Wodinsky, I., Swiniarski, J., and Kensler, CJ. Spleen colony studies of leukemia L1210. I. Growth kinetics of

lymphocytic L1210 cells in vivo as determined by spleen colony assay. Cancer Chemother. Rep. 51, 415-421,

1967 (1-3% total cells forming spleen colonies).

Bergsahel, DE & Valeriote FA. Growth characteristics of a mouse plasma cell tumor. Cancer Res. 28, 2187-2196,

1968 (<4.4% cells are tumor stem cells).

Park CH, Bergsagel DE, and McCulloch, EA. Mouse myeloma tumor stem cells: a primary cell culture assay.

JNCI 46, 411-422, 1971 (0.7 - 1.2% clonogenic, tumor stem cells).

Hamburger, A.W. and Salmon SE. Primary bioassay of human tumor stem cells. Science 197, 461-463, 1977

0.001 - 0.1% myeloma cells forming colonies in soft agar).

Fidler, IJ and Kripke, ML. Metastasis results from preexisting variant cells within a malignant tumor. Science

197, 893-895, 1977.

Salmon, SE, Hamburger, A.W., Soehnlen, B., Durie, B.G.M., Alberts, D.S., and Moon, T.E.. Quantitation of

differential sensitivity of human -tumor stem cells to anticancer drugs. N. Eng. J. Med. 298, 1321

-1327, 1978.

Sell, S., and Pierce, G.B. Maturation arrest of stem cell cell differentiation is a common pathway for the cellular

origin of teratocarcinomas and epithelial cancers. Lab. Invest. 70, 6-22, 1994.

Trott, KR. Tumor stem cells: the biological concept and its application in cancer treatment. Radiother. Oncol.

30, 1-5, 1994.


A Cancer Cells

C

Du145

B

D

LNCaP

Evidence for CSCs: Long-term cutured cancer cells have only

a minor subset of clone-initiating cells

a


Only 0.01 -0.1% of the actutely purified tumor cells Cancer Cells

have the sphere-forming abilities


Leukemic stem cells (LSC): Classic examples of CSC Cancer Cells

  • Lapidot T, et al. A cell initiating human acute myeloid leukaemia after

  • transplantation into SCID mice. Nature 367, 645-648, 1994.

  • Blair et al., Blood 89, 3104-3112, 1997

  • Bonnet, D., & Dick, J.E. Nature Med. 3, 730-737, 1997

  • Most of the leukemic cells are unable to proliferate extensively and only

    a small, defined subset of cells was consistently clonogenic.

  • LSCs for human AML were identified prospectively and purified as

    [Thy1-, CD34+, CD38-] cells from various patient samples and they

    represent 0.2 - 1% of the total.

  • The LSCs are the only cells capable of transferring AML from human

    patient to NOD/SCID mice and are referred to as SCID leukemia

    -initiating cells (SL-IC).


Identification of CSC in Solid Tumors by Markers Cancer Cells

Al-Hajj, M et al., Prospective identification of tumorigenic breast cancer cells. PNAS 100, 3983-3988, 2003.

Hemmati, H.D et al., Cancerous stem cells can arise from pediatric brain tumors. PNAS 100, 15178-15183, 2003 (using neural SC markers).

Galli R et al., Isolation and characterization of tumorigenic, stem-like

neural precursors from human glioma. Cancer Res. 64, 7011, 2004.

Singh SK et al. Identification of human brain tumour initiating cells.

Nature 432: 396-401, 2004 (using CD133 as a marker).

Patrawala L, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene25, 1696-1708, 2006.


Identification of CSCs by SP Cancer Cells

Kondo T, et al. Persistence of a small population of cancer stem-like cells

in the C6 rat glioma cell line. PNAS 101: 781-786, 2004.

Hirschmann-Jax C, et al. A distinct "side population" of cells with high

drug efflux capacity in human tumor cells. PNAS 101: 14228, 2004.

Patrawala, L., et al. Side population (SP) is enriched in tumorigenic,

stem-like cancer cells whereas ABCG2+ and ABCG2- cancer cells

are similarly tumorigenic. Cancer Res. 65, 6207, 2005.

Haraguchi N, et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24, 506-13, 2006.

Chiba T, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44:240-51, 2006.

Szotek PP, et al., Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. PNAS 103:11154-9, 2006.


Identification of putative CSCs by quiescence Cancer Cells

Pece S, et al., Biological and molecular heterogeneity of breast cancer correlates with their cancer

Stem cell content. Cell 140, 62-73, 2010.


TSS (+1) Cancer Cells

ATG (164)

K5 promoter

Exon 1

718

116

Identification of putative CSCs by promoter tracking

Exon 2

-1187


Identification of CSCs by lineage tracing Cancer Cells

Chen J et al., Nature. 2012 Aug 23;488(7412):522-6. A restricted cell population propagates

glioblastoma growth after chemotherapy.

Schepers AG et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal

adenomas. Science 337: 730-735, 2012.

Driessens G et al. Defining the mode of tumor growth by clonal analysis. Nature 488: 527-530,

2012.


Where did tumor cells come from? Cancer Cells

Differentiation

Transformation

probability

Self-renewal

LT-SC

ST-SC

Late

progenitors

Differen-

tiating cells

Differen-

tiated cells

Early

progenitors

Proliferation

Commitment

Niche

Expansion

Differentiation

Tang, Cell Res. 2012


Progenitor or differentiated cells as Cancer Cells

transformation targets or CSCs

Passegue, E., et al. Normal and leukemic hematopoiesis: are leukemias a stem

cell disorder or a reacquisition of stem cell characteristics? Proc. Natl.

Acad. Sci. USA. 100 (Suppl 1): 11842-11849, 2003.

Huntly, B.J., et al. MOZ-TIF2, but not BCR-ABL, confers properties

of leukemic stem cells to committed murine hematopoietic progenitors.

CancerCell. 6: 587-596, 2004.

Jamieson, C.H., et al. Granulocyte-macrophage progenitors as candidate

leukemic stem cells in blast-crisis CML. NEJM. 351: 657-667, 2004.

Krivtsov, AV et al., Transformation from committed progenitor to leukemia

stem cells initiated by MLL-AF-9. Nature 442, 818-822, 2006.

McCormack MP, et al. The Lmo2 oncogene initiates leukemia in mice by

inducing thymocyte self-renewal. Science 327, 879-883, 2010.


Where do tumors REALLY come from? Cancer Cells

Houghton J et al., Gastric cancer originating from bone marrow-derived cells. Science. 2004, 306: 1568-71.

Direkze NC, et al., Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 2004, 64: 8492-5.

Aractingi Set al.,Skin carcinoma arising from donor cells in a kidney transplant recipient. Cancer Res. 2005, 65:1755-60.

Kaplan RNet al.,VEGFR1-positive hematopoietic bone marrow

progenitors initiate the pre-metastatic niche. Nature. 2005, 438, 820-827.

Riggi Net al.,Development of Ewing’s sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005, 65:11459-11468.

Palapattu GSet al.,Epithelial architectural destruction is necessary for bone marrow derived cell contribution to regenerating prostate epithelium. J. Urol, 2006, 176:813-18.


Cancer Stem Cells & Treatment Cancer Cells

Weissman, Nature 414, 105-111, 2001


How to specifically target CSCs? Cancer Cells

*Identify functional CSC molecules (e.g., CD44, c-KIT, Bmi-1, Nanog)  Knock down

these molecules to inhibit CSC properties (e.g., Jeter et al., 2009; Levina V

et al., Elimination of human lung CSCs through targeting of the stem cell

factor-c-kit autocrine signaling loop. Cancer Res. 70, 338-346, 2010).

*Identify CSC-specific cell-surface markers  Develop antibody or prodrug based

therapeutics

*Take advantage of differential signaling requirement between normal and cancer SC

(Yilmaz OH et al., Pten dependence distinguishes haematopoietic stem cells

from leukaemia-initiating cells. Nature. 2006 441:475-82)


Using stem/progenitor cells to treat tumors: Cancer Cells

*Using neural progenitor cells alone: these cells produce large amounts of TGFb

(Staflin et al., Cancer Res. 64, 5347-5354, 2004)

*Using neural progenitor cells to deliver cytokines or cytotoxic genes or products

--- Benedetti et al., Nat. Med. 6, 447-450, 2000

--- Aboody et al., PNAS 97, 12846-12851, 2000

--- Herrlinger et al., Mol. Ther. 1, 347-357, 2000

--- Ehtesham et al., Cancer Res. 62, 5657-5663, 2002

--- Ehtesham et al., Cancer Res. 62, 7170-7174, 2002

--- Barresi et al., Cancer Gene Ther. 10, 396-402, 2003

*Using IL23-expressing BM-derived neural stem-like cells to attack glioma cells

--- Yuan X et al., Cancer Res. 66, 2630-2638, 2006

*Using hMSC to attack Kaposi’s sarcoma

--- Khakoo AY et al., JEM. 203, 1235-1247, 2006


‘Reprogramming’ the microenvironment of CSC to Cancer Cells

treat tumors:

Kulesa P et al. Reprogramming metastatic melanoma cells to assume a neural

crest cell-like phenotype in an embryonic microenvironment. PNAS

103, 3752-3757, 2006.

Topczewska JM., et al., Embryonic and tumorigenic pathways converge via Nodal

signaling: role in melanoma aggressiveness. Nature Med. 12, 925-932,

2006.


ad